FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.126,49 +1.717,27 (+2,99%)
Oxford Biomedica plc (OXB.L)
| Chiusura precedente | 300,00 |
| Aperto | 304,00 |
| Denaro | 329,00 x 0 |
| Lettera | 358,00 x 0 |
| Min-Max giorno | 301,53 - 350,00 |
| Intervallo di 52 settimane | 164,29 - 474,50 |
| Volume | |
| Media Volume | 352.232 |
| Capitalizzazione | 328M |
| Beta (5 anni mensile) | 1,03 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,63 |
| Prossima data utili | 29 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 453,86 |
GlobeNewswireOxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect
- GlobeNewswire
Oxford Biomedica to host webinar showcasing the TetraVecta™ system
Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled “4th Generation Lentiviral Vectors: An Improved Gene Delivery System” will feature presentations by D
- GlobeNewswire
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
Oxford Biomedica launches TetraVectaTM - the next generation lentiviral vector system Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of lentiviral vectors, while incorporating new and enhan
